Langerhans Cell Histiocytosis Enters the Genomics Age
This increased understanding of the pathophysiology of Langerhans cell histiocytosis should help guide treatment and therapies and provides the rationale for using agents effective against myeloid malignancies.
The Immunocompromised Traveler
Among immunocompromised travelers, the risk of acquiring travel-related infections may be higher due to deficits in their immune system and their potential to have attenuated responses to vaccines.
Ovarian Carcinoma Histotypes: Their Emergence as Important Prognostic and Predictive Markers
The movement of ovarian carcinoma histotypes from ill-defined and poorly reproducible clusters of cases to distinct disease entities clearly has beneficial implications for patient management.
Vinay Prasad on the Use of Exaggerated Language in Cancer Research, and How It Can Mislead Doctors, Patients, and the Public
Metastatic HER2-Positive Breast Cancer: Tailoring Treatment Un-‘TIL’ We Get It Right...
While we continue to be thankful for incremental gains in the treatment of our patients with metastatic HER2-positive breast cancer, much work remains in order to optimize and individualize care.
Oslerian Genomics for Prostate Cancer Oncology
The great strength of the PCWG3 is the recognition that second- , third- , and fourth-line treatments offer new possibilities for extending overall survival.
2 Commerce Drive Cranbury, NJ 08512